Molecular Basis of Metastasis

Anne C. Chiang, M.D., Ph.D., and Joan Massagué, Ph.D.

METASTASIS IS THE END PRODUCT OF AN EVOLUTIONARY PROCESS IN which diverse interactions between cancer cells and their microenvironment yield alterations that allow these cells to transcend their programmed behavior. Tumor cells thus populate and flourish in new tissue habitats and, ultimately, cause organ dysfunction and death. Understanding the many molecular players and processes involved in metastasis could lead to effective, targeted approaches to prevent and treat cancer metastasis.

The tumor–node–metastasis (TNM) staging system used for most solid tumors considers the tumor size and degree of local invasion (T), the number, size, and location of lymph nodes (N), and the presence or absence of distant metastases (M).

Metastases of tumors originating in different sites, such as the breast or lung, are treated differently because they are thought to behave like the tissue of origin, with characteristic patterns and kinetics of spread, and distinct profiles of chemosensitivity. Lymph nodes are of paramount importance in current staging practices, but it is hard to interpret the clinical significance of the distance of metastases from the primary site (e.g., a supraclavicular N3 vs. a mediastinal N2 lymph node in lung cancer). Indeed, the distance from the primary tumor to the organ of metastasis does not affect staging. For this reason, the real value of staging is to serve as an indicator of the primary cancer’s composite capability to metastasize, rather than to ensure that the tumor lies within the prescribed limits of a local intervention. Recent advances bring hope for characterizing the metastatic behavior of cancer cells beyond the simplistic TNM stage. In the future, staging could include identification of subpopulations of tumor cells that have different metastatic behavior. A deeper understanding of the molecular and genetic concepts and processes involved in metastasis may pave the way toward new prognostic models and ways of planning treatment.

ORIGINS OF CELLULAR HETEROGENEITY

Primary tumors consist of heterogeneous populations of cells with genetic alterations that allow them to surmount physical boundaries, disseminate, and colonize a distant organ. Metastasis is a succession of these individual processes (Fig. 1), and fully metastatic cells are rare clones in the primary tumor. In animal models, 0.01% or fewer of the cancer cells entering the circulation develop into metastases.

The intrinsic genomic instability of cancer cells increases the frequency of alterations necessary to acquire metastatic capacity. The genomic instability and heterogeneity of tumor cells are apparent in the chromosomal gains, losses, and rearrangements associated with cancer. DNA integrity can be compromised by aberrant cell-cycle progression, telomeric crisis (i.e., telomere dysfunction characterized by cytogenetic abnormalities and chromosomal instability), inactivation of DNA repair
genes (see the Glossary), and altered epigenetic control mechanisms. For example, 50% of cancers have lost the tumor-suppressor protein p53, which responds to DNA damage by inducing apoptosis or arresting cell growth. Loss of p53 allows the accumulation of cells with DNA damage.

**SELECTIVE PRESSURES OF THE TUMOR MICROENVIRONMENT**

Each tissue has a physical structure and an established functional anatomy complete with compartmental boundaries, a vascular supply, and a characteristic extracellular milieu of nutrients and stroma. Cancer cells that circumvent this organization become exposed to environmental stresses, including a lack of oxygen or nutrients, a low pH, reactive oxygen species, and mediators of the inflammatory response. Such pressures can select tumor cells with the capability of growth despite these challenges and in the process can cause them to acquire an aggressive phenotype. For example, hypoxia stabilizes hypoxia-inducible factor (HIF), which cues a program of gene expression that leads to changes in anaerobic metabolism, angiogenesis, invasion, and survival. HIF boosts the expression of lysyl oxidase; lysyl oxidase regulates the activity of focal adhesion kinase in a way that enhances cell-matrix adhesion and invasion.

High levels of lysyl oxidase correlate with shorter metastasis-free survival and a poor prognosis in head and neck cancer, as well as in estrogen-receptor-negative breast cancer. Another product of HIF-induced gene activation, the chemokine (C-X-C motif) receptor CXCR4, together with its ligand, the chemokine stromal-cell–derived factor 1 (SDF-1, also called CXC chemokine ligand 12 [CXCL12]),
facilitates the survival of cancer cells at sites of metastasis in breast cancer and renal-cell cancer.\textsuperscript{13}

**Cancer Stem Cells and Metastasis**

The question of the extent to which self-renewing cancer stem cells initiate and sustain cancers of different types is a subject of intense investigation, and there are probably different answers according to different tumor types. Such cells are envisioned as a subpopulation of cancer cells that—by one mechanism or another—have the capacity to act as tumor-propagating cells.\textsuperscript{14}

These cells might resist apoptosis and DNA damage caused by drugs; they might also require a niche or specific microenvironment in order to grow.\textsuperscript{15} Such attributes would support the establishment of both primary and metastatic tumors. The SDF-1–CXCR4 axis is thought to function in support of cancer cells and stem cells or precursor cells.\textsuperscript{16} A “premetastatic” niche has been described in animal models in which bone marrow–derived progenitor cells home to specific distant sites before the formation of a metastasis.\textsuperscript{17,18} The ability of stem cells to evade destruction and survive in distant sites, including the bone marrow, may explain why micrometastases can remain dormant after removal of the primary tumor, only to recur years later.

---

**Glossary of Selected Genes**

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Gene Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANGPTL4</td>
<td>Angiopoietin-like 4</td>
</tr>
<tr>
<td>APC</td>
<td>Adenomatous polyposis coli</td>
</tr>
<tr>
<td>BRAF</td>
<td>(Also known as V-raf murine sarcoma viral oncogene homologue B1)</td>
</tr>
<tr>
<td>BRCA1</td>
<td>Breast-cancer gene 1</td>
</tr>
<tr>
<td>COX2</td>
<td>Cyclooxygenase-2</td>
</tr>
<tr>
<td>CSF1</td>
<td>Colony-stimulating factor 1</td>
</tr>
<tr>
<td>CTGF</td>
<td>Connective-tissue growth factor</td>
</tr>
<tr>
<td>CXCR4</td>
<td>CXC chemokine receptor 4</td>
</tr>
<tr>
<td>EGF</td>
<td>Epidermal growth factor receptor</td>
</tr>
<tr>
<td>EGFR</td>
<td>Epidermal growth factor receptor</td>
</tr>
<tr>
<td>FGFR</td>
<td>Fibroblast growth factor receptor</td>
</tr>
<tr>
<td>HER2</td>
<td>Human epidermal growth factor receptor type 2</td>
</tr>
<tr>
<td>ID1</td>
<td>Inhibitor of differentiation-1</td>
</tr>
<tr>
<td>MMP1</td>
<td>Matrix metalloproteinase 1</td>
</tr>
<tr>
<td>MMP9</td>
<td>Matrix metalloproteinase 9</td>
</tr>
<tr>
<td>NEDD9</td>
<td>Neural precursor cell expressed, developmentally down-regulated 9</td>
</tr>
<tr>
<td>P13K</td>
<td>Phosphoinositide 3-kinase</td>
</tr>
<tr>
<td>PTEN</td>
<td>Phosphatase and tensin homologue</td>
</tr>
<tr>
<td>RANKL</td>
<td>Ligand for the receptor activator of nuclear factor-κB</td>
</tr>
<tr>
<td>RHoC</td>
<td>Ras homologue gene family, member C</td>
</tr>
<tr>
<td>STK11</td>
<td>Serine–threonine kinase 11 (also known as LKB1)</td>
</tr>
<tr>
<td>TWIST1</td>
<td>Twist homologue 1</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
<tr>
<td>VHL1</td>
<td>von Hippel–Lindau 1</td>
</tr>
</tbody>
</table>

**Invasion and Epithelial-to-Mesenchymal Transition**

In many primary tumors with invasive properties, intercellular adhesion is reduced, often because of a loss of E-cadherin, a direct mediator of cell–cell adhesive interactions. The cytoplasmic tail of E-cadherin is tethered, via α-catenin and β-catenin, to the actin cytoskeleton; one of actin’s properties is to maintain cell junctions. The importance of maintaining intercellular adhesion was shown in a mouse model of pancreatic cancer in which disruption of the expression of E-cadherin led to early invasion and metastasis.\textsuperscript{19} Various mechanisms can cause a loss of E-cadherin: mutations resulting in an inactive protein, gene silencing by promoter methylation, or down-regulation stimulated by growth factor receptors (e.g., epidermal growth factor receptor [EGFR], fibroblast growth factor receptor [FGFR], insulin-like growth factor I [IGF-I] receptor, and MET) or SRC family kinases.\textsuperscript{19,20} Expression of the E-cadherin gene (CDH1) is also inhibited by several transcriptional repressors.\textsuperscript{21,22} Loss of E-cadherin function is necessary, though not sufficient for epithelial-to-mesenchymal transition, a process whereby epithelial cells switch to a mesenchymal progenitor-cell phenotype, enabling detachment and reorganization of epithelial-cell sheets during embryonic development, as well as tumor invasion and metastasis.\textsuperscript{23}

**Motility and Extracellular-Matrix Remodeling**

The extracellular matrix serves as a scaffold along which cells attach and move by means of contacts between cell-surface receptors called integrins and extracellular-matrix components such as fibronectin, collagen, and laminin. Integrins also interact in a cytoplasmic complex consisting of focal adhesion kinases and SRC family kinases to mediate attachment to the actin cytoskeleton.
Through calcium-dependent guanosine triphosphatases (GTPases), extracellular-matrix signals cause cytoskeletal changes that form individual cytoplasmic extensions called filopodia, which coalesce into larger lamellipodia, structures that are important in migratory movement. Expression profiling of melanoma cell lines obtained by means of in vivo selection has shown that the calcium-dependent GTPase RhoC is important in lung metastasis. Homozygous RhoC-deficient mice have normal formation of primary tumors but impaired cancer-cell mobility and almost no lung metastases. NEDD9, a scaffolding protein involved in cell adhesion, colocalizes in focal contacts with focal adhesion kinase and can promote cell motility and invasion. Various members of the matrix metalloproteinase (MMP) family (e.g., MMP-2 and MMP-9) are also implicated in cancer-cell invasion. Independent screens for genes that mediate bone or lung metastasis in breast cancer have identified MMP-1 as being necessary for spread to the bone and lungs. The metastasis-suppressor microRNA miR335, which inhibits metastasis to the lungs and bones in human breast-cancer xenografts, suppresses the expression of two mediators of cancer-cell invasion, the transcription factor SOX-4 and tenasin-C, a matrix glycoprotein. A low level of miR335 in breast-cancer cells is associated with relapse.

**STROMAL INTERACTIONS**

Not only are cancer cells able to traverse the structural boundaries of the primary tumor, but they can also co-opt local and bone marrow–derived stromal-cell responses to their advantage. At points of basement-membrane invasion in mouse tumors, tumor-associated macrophages proliferate in response to tumor-derived colony-stimulating factor 1 and produce growth factors (e.g., fibroblast growth factor, EGFR ligands, and platelet-derived growth factor [PDGF]) and proteases (e.g., MMPs and cathepsins). In addition, tumor-associated macrophages activate a particular type of carcinoma-associated mesenchymal cell, the myofibroblast, which secretes the cytokine SDF-1; this cytokine enables the myofibroblast to recruit endothelial progenitor cells. Impaired metastases of breast-cancer cells to the lungs occur in mice with genetic defects in macrophages. The stroma-derived cytokine, transforming growth factor β (TGF-β), induces the expression of genes such as ANGPTL4 in breast-cancer cells; TGF-β enhances metastatic activity and is associated with increased metastases to the lungs in estrogen-receptor–negative breast cancer. In short, several types of stromal cells and their secreted factors provide selective prometastatic advantages.

**ORGAN-SPECIFIC METASTASIS**

Some types of cancers have a characteristic proclivity to metastasize to certain organs, but not to others (Fig. 2). Breast cancer spreads to
the bones, lungs, brain, and liver; distant metastases of prostate cancer occur most prominently in bone. Breast-cancer and prostate-cancer cells can both spread to and colonize the bone, but they form osteolytic or osteoblastic metastases, respectively. According to Paget’s “seed” vs. “soil” hypothesis, perceived compatibilities between disseminated cancer cells (the seed) and certain distant sites (the soil) have long influenced our view of the metastatic process.43

The formation of bone metastases alters bone homeostasis — the balance of action of osteoclasts in degrading bone against the constant rebuilding of bone by osteoblasts. Breast-cancer cells preferentially cause osteolytic lesions by inducing osteoclasts to secrete PTHrP (parathyroid hormone–related peptide), tumor necrosis factor α (TNF-α), and cytokines such as interleukin-1, interleukin-6, interleukin-8, and interleukin-11. These factors cue osteoblasts to release RANKL (the ligand for the receptor activator of nuclear factor-κB [RANK]), which stimulates osteoclast differentiation (Fig. 3). Osteoclasts demineralize bone, thereby causing the release of growth factors such as bone morphogenetic proteins, IGF-1, and TGF-β from the exposed bone matrix; all these growth factors support cancer-cell proliferation and induce further release of PTHrP. In a breast-cancer xenograft model, breast-cancer cells that preferentially colonized bone had up-regulated expression of genes encoding CXCR4, osteopontin, CTGF, MMP-1, and interleukin-11.30 By contrast, prostate-cancer cells secrete osteoblast-stimulating factors such as Wnt family ligands, bone morphogenetic proteins, PDGF, and endothelin-1; these factors stimulate formation of the hallmark osteoblastic metastases of prostate cancer. Tumor-derived signals suppress the ability of osteoblasts to secrete osteoprotegerin, a RANKL antagonist that blocks RANK–RANK interaction and resulting osteoclast activation. Thus, factors secreted by cancer cells, or “seeds,” can influence the type of metastases formed.

Cancer cells may regulate the expression of other molecules to target colonization in other organs.44 Such molecules include the gene encoding ezrin (an intracellular protein needed for early survival of metastatic osteosarcoma cells in the lung), serine–threonine kinase 11 (STK11, also known as LKB1) (a metastasis-suppressor gene regulating NEDD9 in lung cancer45), and genes in an 18-gene breast-to-lung metastatic gene-expression signature including the EGFR ligand EREG, COX-2, MMP-1, ANGPTL4, and other mediators of infiltration and colonization by cancer cells in the lung.46

The soil, or distant metastatic site, is a largely nonpermissive environment, as evidenced by the rarity of metastatic clones arising after injecting millions of cells into circulation in experiments in animals. In humans, also, thousands of circulating tumor cells have been found in the absence of metastases. Certain seed–soil interactions can support the cancer cell’s ability to survive in the metastatic microenvironment, including the RANKL–RANK interaction. Another example involves the SDF-1 chemokine in the bone marrow, which recruits breast-cancer and prostate-cancer cells and enhances their survival.47 Whereas the mechanisms of metastasis to bone and lung have been extensively studied and are partially understood, there is a dearth of information about the molecular basis for metastasis to other organs, such as the liver and brain.

### An Integrated Model of Metastasis

In the past decade, our view of metastasis has changed from snapshots detailing specific biologic processes to a moving picture of how various cancer cells acquire functions and co-opt stromal signals for spread and encampment in a distant site. Random genetic and epigenetic alterations in cancer cells in combination with a plastic and responsive microenvironment support the metastatic evolution of tumors. Moreover, genes needed at individual steps along the metastatic process have been identified.

These genes have been classified into three categories: initiation, progression, and virulence48 (Fig. 1). Genes that are associated with metastatic progression give the cancer cell particular advantages at multiple points during its sojourn to a distant site. These advantages can influence the cell’s metastatic destination. Genes associated with the initiation of metastasis and virulence operate in the earliest and latest stages of invasion and growth in the primary tumor and different metastatic habitats, respectively. The use of such a framework to organize specific genes and their functions allows a multidimensional picture (including locale and time) of metastasis and may aid in the development of rational antimetastatic strategies.
Early theories of metastasis pitted models of genetic predetermination against those of orderly anatomic progression. The advent of molecular genetics has refashioned the model of tumor progression in which somatic mutations were thought to accumulate sequentially, resulting in rare cells capable of metastasis.49 Other models emphasize dynamic heterogeneity and clonal selection, principles that suggest that an unstable metastatic
variant can expand and prevail in the population of cells. The presence of metastasis genes in gene-expression signatures of primary tumors would seem to challenge the traditional tumor-progression model of somatic evolution in which metastatic cells would be too rare to influence a population-averaged gene-expression profile of the primary tumor. This finding, however, probably reflects an abundance of partially competent cancer cells that have accumulated a sufficient number of malignant functions to promote expansion of the primary tumor, and which may be necessary but not sufficient for forming metastases. By contrast, genes associated with metastatic virulence provide an aggressive edge in survival and proliferation solely during colonization of the metastatic site (Fig. 1). Many of these genes do not give the primary tumor a selective advantage, and thus they would not be represented in gene signatures of the primary tumor.

**METASTASIS-PROGRESSION GENES**

Genes that are necessary for certain functions such as vascular remodeling can participate in both the primary tumor and the metastatic environment; these genes are metastasis-progression genes, and they could be enriched in primary tumors (Fig. 1). An 18-gene lung-metastatic signature derived from selected in vivo breast-cancer cells that efficiently spread to the lungs includes **EREG**, **COX-2**, and **MMP-1**. These genes cooperate in remodeling the vasculature in sites of mammary tumors and lung metastasis. In the breast, they allow neoangiogenesis and intravasation of cancer cells; in the lung, they mediate extravasation of circulating cancer cells from capillaries into the parenchyma. Breast cancers with the lung-metastatic signature have a high risk of lung metastases, but not of metastases to the bones or liver. A likely explanation is that extravasation is not essential for passage through the fenestrated vasculature of the bone marrow and liver sinusoids. Thus, metastasis-progression genes may couple the tissue-specific features of the microenvironment in a particular organ to a matching role in the progression of a primary tumor. Expression of the lung-metastatic signature gene **ANGPTL4** is a bystander event in mammary tumors, but when cancer cells expressing **ANGPTL4** reach lung capillaries, its role in mediating extravasation by disrupting endothelial cell–cell contacts becomes manifest.

Both the cells of primary tumors and metastatic cells require the ability to initiate self-renewal and bypass senescence. ID1 (inhibitor of differentiation-1) is the sole transcriptional regulator in the lung-metastatic signature, and it can be found in clusters of cancer cells within breast tumors of the basal or triple-negative (i.e., estrogen-receptor–negative, progesterone-receptor–negative, and human epidermal growth factor receptor type 2 [HER2]–negative) subtype. Suppression of ID1 expression inhibits the initiation of mammary tumors and metastases in the lungs. Thus, ID1 may promote micrometastatic outgrowth from dormancy at the metastatic site. Related to this function, in mouse models of metastatic breast cancer, ID1 cooperates with activated RAS oncoproteins to avert cell senescence.

**METASTATIC DISSEMINATION**

Cancer cells can disseminate from a tumor very early in the life of a tumor. They have been detected in the bone marrow of patients with breast cancer with early-stage disease. Such cancer cells were genetically distinct from the matched primary tumors, but bone marrow–derived cancer cells in patients with overt metastatic disease were less genetically disparate. This finding may reflect differences between the departure time from the primary neoplasm and the duration of exposure to selective pressures. Dormant cancer cells isolated from the bone marrow of transgenic mice with preinvasive breast cancer and patients with ductal carcinoma in situ became activated when transplanted into the bone marrow and caused the growth of lethal tumors. Many mechanisms for metastatic dormancy have been postulated. In patients with advanced metastatic disease, breast cancer cells that are competent in vascular entry can efficiently exit at a distant organ and perhaps reenter to repeat the process. Tumor infiltration by means of its own circulating progeny of metastatic cancer cells has been raised as a possible mechanism for the later rapid expansion of tumor growth. According to this hypothesis, large primary tumors may also be the end product of aggressive reseeding. This would be a new perspective on the long-standing observation that metastatic relapse correlates with tumor size.
Gene-expression signatures of primary breast cancers that predict clinical outcome generally do not overlap and range from a 70-gene “poor-prognosis” signature (detected with the use of the MammaPrint test) to a hand-picked set of 21 “recurrence” genes (detected with the use of the Oncotype Dx test) that includes estrogen-receptor, HER2, and proliferation markers. Other signatures consist of genes with expressions that are associated with a process or pathway, such as the response to serum mitogens, hypoxia, activation of specific oncogenes (e.g., RAS, MYC, and SRC), stimulation with a growth factor (e.g., TGF-β), or treatment with specific chemotherapeutic drugs to establish a drug-sensitivity profile. To specifically identify genes that mediate metastasis, animal models have been used to select in vivo for highly metastatic and organ-specific derivatives of human cancer cell lines. Such signatures can correlate with bone-specific and lung-specific spread. The lung-metastasis signature further correlates with clinical outcome, including the recurrence of disease in the lungs, in primary breast-cancer tumors. Functional validation approaches (e.g., overexpression or knockdown experiments in culture or xenograft experiments) have confirmed that these genes, particularly in combination, are critical for metastatic functions.

TARGETS OF THERAPY

In principle, each metastasis-specific gene is a potential target for a treatment. Ongoing clinical trials target the metastatic initiation gene c-MET (e.g., the small-molecule inhibitor ARQ 197, in phase 1–2 trials) and two metastatic virulence genes, RANK ligand (e.g., denosumab, in phase 3 trials) and TGF-β (e.g., monoclonal antibody GC1008, in phase 1 trials). Combination therapy may be needed to overcome the intrinsic biologic redundancy in metastasis and to target sequential steps in metastasis. In one series of preclinical experiments, only combination (not single-agent) therapy with the drugs celecoxib and cetuximab, meant to target two metastatic progression genes, was effective in blocking lung metastases by highly lung-metastatic breast-cancer cells. If cancer cells are constantly on the move between sites of metastasis in the lung, treatment with these drugs could prevent further reseeding and growth of metastatic sites. Cancer treatment may need to combine multiple antimetastatic drugs with cytotoxic chemotherapy. For example, bevacizumab, an antibody targeting vascular endothelial growth factor, is being studied in combination with chemotherapy in the adjuvant setting for colorectal, ovarian, and non–small-cell lung cancers. Therapies that target the mechanisms that keep dormant micrometastases alive are also needed.

CLINICAL TRANSLATION

Clinical trials involving antimetastatic agents face a number of obstacles. Any adjuvant trial to assess the recurrence of metastatic disease requires many patients because of the infrequency and long time to progression of metastatic disease in many types of cancer. Measuring response rates beyond stable disease will further increase the number of patients in a trial. Moreover, correlative studies of tissue obtained from metastatic sites are essential to understand the results of such trials. These barriers are sobering, and they perhaps underscore the conceptual shifts that will be needed for the development of new cancer therapies. What changes can we envision? The profile of a tumor could include not only histopathological or genetic determinants, or both, but also a molecular snapshot that would indicate a “metastasis quotient.” The metastasis quotient could be a measure of how adept the cells are with respect to metastatic functions, and it could serve as a prognostic framework. By focusing on metastatic progression and virulence functions, cancer therapy might be dictated by the metastatic site and not only by the specific tissue of origin. A current example of a treatment targeting a metastatic organ is the use of bisphosphonates or denosumab (an anti-RANK antibody), or both, to treat bone metastases originating from the breast, lung, and even multiple myeloma. Drug regimens for patients with cancer might include multiple drugs targeting different metastatic sites and seeding among sites. There is now hope for achieving the ultimate goal — curing metastatic disease.

Dr. Massagué reports receiving consulting fees from Acceleron Pharmaceuticals, lecture fees from Eli Lilly, Genzyme, and Eisai. No other potential conflict of interest relevant to this article was reported.

We thank D. Nguyen, G. Riely, K. Politi, and D. Spriggs for insightful discussions.
REFERENCES


52. Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodelling co-

The New England Journal of Medicine
Downloaded from nejm.org at UNIV OF PENN LIBRARY on June 10, 2022. For personal use only. No other uses without permission.
Copyright © 2008 Massachusetts Medical Society. All rights reserved.


Copyright © 2008 Massachusetts Medical Society.